




An opportunity to invest
in a transformational
Canadian Life Sciences Company

scimar.ca

Information Deck 2023

The Problem

- 537 million people have diabetes, a 3X increase since 2000.
- 643 million people are projected to develop diabetes by 2030.
- 90% of all cases are type 2.
- Millions more are prediabetic or undiagnosed.
- Total diabetes-related health expenditures will reach one trillion USD by 2030.



The **Solution** Is Found Beyond Insulin

For the past 100 years, diabetes treatment has focused strictly on the pancreas and the hormone it produces: **insulin**.

We have discovered a second hormone — produced by the liver — that plays a key role in metabolic health.

This hormone is called **hepatalin**. It is the missing link that explains why current treatments haven't slowed the diabetes epidemic.

Hepatalin: “The Missing Link”

- Hepatalin is a hormone that stores excess **glucose in muscle**.
- Insulin is a hormone that stores excess **glucose in fat**.
- The ability to produce hepatalin declines **due to age, lifestyle, and consumption of refined sugar**.
- People with type 2 diabetes **are lacking hepatalin (not insulin)**.

The Way Forward: Four Products

SciMar is developing a complete hepatalin product suite

1. **SciMar NuPa Test** – diagnostic
2. **SciMar NuPa Daily** – nutraceutical
3. **SciMar NuPa Renew** – pharmaceutical
4. **Hepatalin-S Synthetic** – hormone

The Way Forward: Four Products

1. SciMar NuPa Test

A powdered beverage mix, specially formulated to measure the production of hepatalin.

- R&D study completed Sep 2021
- Proof-of-concept study completed Jan 2022
- Target approval for market:

Canada 2024/25

USA 2025/26

**Patents: U.S., Canada, Australia, U.K., Germany, France
(international patent expansion underway)**



The Way Forward: Four Products

2. SciMar NuPa Daily

A nutraceutical designed to protect the liver and its production of hepatalin.

- Licensed by Health Canada in 2022.
- Market claims differentiation trial: 2024.
- Target in-market: U.S. in 2024.
- Discussions underway to launch in Europe, Middle East, Africa, and China.

Patent: U.S. (international patent expansion underway)



The Way Forward: Four Products

3. SciMar NuPa Renew

A prescription medication taken before each meal to renew hepatalin production for the duration of digestion.

- Product formulation studies currently underway
- Dose and timing trials: 2024
- Target in-market:

Canada 2027/28

USA 2028/29

Patents: USA, Canada, China, Australia, United Kingdom, Germany, France, Japan, New Zealand, Hong Kong



The Way Forward: Four Products

4. A Synthetic Version of Hepatalin

Scimar is moving synthetic candidates through a proteomics confirmation process.

The company is exploring industry collaborations and strategic partners to commercialize.

A synthetic version of hepatalin (Hepatalin-S) would be used alongside insulin as a more complete therapy for people living with late-stage diabetes.

**Patents: U.S., Canada, Australia, U.K., Germany, France
(international patent expansion underway)**



30 Years of **Academic Research:**

Working over 30 years as an academic, Dr. W. Wayne Lutt attracted \$17.3 million in academic grants and private/commercial support, including grants from:



Custom-Built Clinical Trials Facility

Wellness Transformation Network (WTN) — Our community outreach initiative designed to promote healthy lifestyles; measure the impact of specific lifestyle interventions through the lens of hepatalin; and serve as a platform to test the NuPa family of products in a clinical setting.



Executive Team



Mick Lautt

Chief Executive Officer

Co-founded Scimar in 2009 to commercialize Scimar's discoveries.

Seasoned entrepreneur; 25 years in corporate consulting across diverse industries; expert in organizational development, management, leadership, and community outreach



Dr. W. Wayne Lautt

Chief Science Officer

Co-founded Scimar in 2009 to bring his breakthrough discoveries to market.

Professor Emeritus, University of Manitoba; Michael Smith Award-winner in scientific research; and author of more than 215 peer-reviewed publications.

Executive Team



John West

Chief Development Officer

Joined Scimar in 2015 to develop Scimar's business plan into a de-risked project plan.

20-year background in strategy; consultant for world's largest companies in big data, business analytics, e-commerce, software development, supply chain, forecasting, and growth.



Allison Barsewsky

Chief Financial Officer

Financial planning, accounting, tax, and audit experience in public practice since 2013, serving large businesses, start-ups, agricultural producers, and non-profits.

31 Fulltime Staff and Contractors

10 Members on Advisory Board

5 Members on Board of Directors

Our team is supported by 3rd party experts in patents, trademarks, intellectual property, manufacturing, regulatory affairs, marketing, e-commerce, shipping, logistics, and clinical trial management.


[Meet the rest of Scimar's team](#)



Importance of **Timing**

- The global rates of type 2 diabetes are growing exponentially. **The health of future generations is at risk.**
- **Hepatalin research** by other parties is progressing rapidly, but we have a ten-year head start.
- COVID-19 has opened people's eyes to the benefits of working together. The world community is ready to take on the next **global health crisis.**

SciMar's Historical Valuation



Raise History (In Canadian Dollars)

Public funds, grants, and incubator investments:	\$17.3M
Seed round, 2018:	\$10.2M in preferred common units
Bridge round, 2021/22:	\$4.3M in convertible preferred shares
Series A, 2022/23:	\$5M in common shares



Thank you!

For further information,
please contact:

Email us at invest@scimar.ca or visit scimar.ca

scimar.ca